Q: Hello Peter,
I am wondering if it is best to sell my positions in Lumine Group and Topicus and use the proceeds to beef up my position in Constellation as it seems the subsidiaries are hardly moving and are range bound..Also, can you suggest a few money market funds that i can park my money into.. Much appreciate it
Q: Constellation Software has impressively continued to climb to new 52 week highs. Topicus and Lumine have been pretty stagnant lately. Do you expect some share price action from Topicus and Lumine in the next 6 months?
Q: I enjoy reading Howard Marks of Oaktree ; so much common sense dealing with investing.
Do you have favourite authors that you would suggest having themes on investing ?
Thanks . Derek
Q: Hi, hold enough EIF that I want to divest and diversify. Looking for high growth over the next 4-5 years, but not as interested in dividends. I also hold a fair bit of CSU and gsy, so am thinking along those lines. What would be a good ranking for the following at today's prices (best to worst), and are there another couple additions you'd suggest? Big thanks!
DOL, BN, CLS, LMN, TOI, DRX, DSG, IFC, TRI, PRL, AFN, GFL.
Q: Hi Team,
I was looking at adding to either Bn, PRL , Eqb, or HPS.A. Or possibly a new purchase of Lulu for a recovery play here . Could you please rank these names in order which you would prefer to buy today for long term capital appreciation? If you feel there are better opportunities you prefer buying today ideas would be appreciated . Thanks
Q: I was doing a high level look at my portfolio in terms of recent vs 3, 5, and 10 yr CAGR and saw what I expected from stellar performers like CSU, TRI, WSP, IFC and DSG. What surprised me was seemingly declining longer term performance (ie pre-dating interest rate changes) from FTS, QSR, GIB.A, and EIF. The balance of the portfolio is holding it’s own or is cyclical or I can see a path to renewed growth/performance. Are the four named really lagging or am I looking at the wrong metrics? If you agree they might be considered to be faltering versus past performance can you suggest “growthier” replacements without going too far out the risk scale? Thank you.
Q: You seem somewhat concerned by the low level of cash for Luimine in the recent report and how under capitalized the business is. This along with the high EV/EBITA ratio. So we be concerned?
Q: This sentence comes from an Goldman Sachs article. What are some examples of the “Utilities” companies referred to here? ….he sees more room for the AI theme to run and expects AI beneficiaries to broaden out beyond just Nvidia, and particularly to what looks set to be the next big winner: Utilities.
Q: Is there an ex-Canada ETF "acceptable to 5i Research" similar to VXC, but perhaps a bit less U.S. exposure. I already have IQLT, so I don't need an ETF that is necessarily ex-North America.
Q: Hello, SPRY is a company developing an alternative treatment for anaphylaxis treatment. I am wondering about the team's thoughts on its current valuation and if it seems reasonable given the company's prospects. Also given favorable inflation data continuing, could this small-cap have good price appreciation potential with lowering interest rates?
Thank you.
Q: I see CI MSCI Canada Quality Index Class ETF (FQC.TO) is no longer available. This was an ETF that seemed to following 5i's investments strategy. It's replacement CI Canada Quality Dividend Growth Index ETF (DGRC.TO) is very different, with a much different sector allocation.
Is there another Canadian ETF that you would recommend as a replacement for FQC, that is similar to the 5i strategy?
Q: YAMCF is Yamaha and was recommended recently on Market Call. I have been watching and it seems to be doing fairly well. It also has another name YAMHF still representing Yamaha. Can you give me your take on Yamaha. SMR was one you had talked about some time ago and is on my 5i Watchlist. It has dropped off considerably. Would you have an update on it?
Q: What is you opinion on STC update release today? It implies revenue growth is returning for fiscal 2025 (as of July 1) and very low debt leverage less than 1.5 X EBITDA by yearend. Currently trading less than 1x revenues with big free cash flow, it seems like a good buy as new Management continues to execute its turnaround.